Pharming Group (NASDAQ:PHAR) Stock Price Up 5.4% – Should You Buy?

Shares of Pharming Group (NASDAQ:PHAR) were up 5.4% on Tuesday . The company traded as high as $9.25 and last traded at $9.59. Approximately 2,252 shares changed hands during trading, a decline of 58% from the average daily volume of 5,358 shares. The stock had previously closed at $9.10.

Analyst Ratings Changes

Several brokerages have recently issued reports on PHAR. HC Wainwright reissued a “buy” rating and issued a $37.00 target price on shares of Pharming Group in a research report on Tuesday, December 17th. Oppenheimer dropped their target price on shares of Pharming Group from $31.00 to $30.00 and set an “outperform” rating on the stock in a report on Monday, October 28th. Finally, Jefferies Financial Group assumed coverage on shares of Pharming Group in a research note on Monday, December 9th. They issued a “buy” rating and a $14.00 price target for the company.

Pharming Group Trading Down 0.5 %

The firm has a 50 day moving average of $9.07 and a two-hundred day moving average of $8.43. The company has a debt-to-equity ratio of 0.41, a current ratio of 3.53 and a quick ratio of 2.76.

Hedge Funds Weigh In On Pharming Group

A hedge fund recently raised its stake in Pharming Group stock. Silverberg Bernstein Capital Management LLC grew its position in Pharming Group (NASDAQ:PHAR) by 16.8% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 47,997 shares of the company’s stock after buying an additional 6,887 shares during the period. Silverberg Bernstein Capital Management LLC owned approximately 0.07% of Pharming Group worth $483,000 as of its most recent SEC filing. Institutional investors and hedge funds own 0.03% of the company’s stock.

About Pharming Group

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.